Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Rhea-AI Summary

Revance Therapeutics (Nasdaq: RVNC) will announce its second quarter 2021 financial results on August 5, 2021, after market close. A conference call and live webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the outcomes and business updates. Individuals can access the call by dialing specified numbers or through the webcast on Revance's investor relations webpage. Revance focuses on innovative aesthetic and therapeutic solutions, including the DaxibotulinumtoxinA for Injection, which is nearing U.S. regulatory approval after a successful Phase 3 program.

Positive

• Successful completion of Phase 3 program for DaxibotulinumtoxinA for Injection.
• Pursuing U.S. regulatory approval for DaxibotulinumtoxinA for Injection.

Negative

• None.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2021 financial results on Thursday, August 5, 2021, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 9755488; or from the webcast link in the investor relations section of the company's website at: www.revance.com.

A replay of the call will be available beginning August 5, 2021, at 4:30 p.m. PT / 7:30 p.m. ET to August 6, 2021, at 4:30 p.m. PT / 7:30 p.m. ET. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference conference ID: 9755488. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005047/en/

FAQ

When will Revance Therapeutics announce its second quarter 2021 financial results?

Revance Therapeutics will announce its second quarter 2021 financial results on August 5, 2021, after the market close.

What time will Revance's conference call be on August 5, 2021?

The conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2021.

How can I listen to Revance's conference call?

You can listen to the conference call by dialing (855) 453-3827 for domestic calls or (484) 756-4301 for international calls, referencing conference ID: 9755488, or via the webcast link on their investor relations website.

What products is Revance Therapeutics focused on?

Revance Therapeutics is focused on innovative aesthetic and therapeutic products, including DaxibotulinumtoxinA for Injection and a range of FDA-approved dermal fillers.

What recent milestone has Revance achieved with its DaxibotulinumtoxinA product?

Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar lines and is pursuing U.S. regulatory approval.